Sensient (SXT) Form 4: Director Fee Deferral Adds 389 Shares

Rhea-AI Filing Summary

Dr. Joseph Carleone, a director of Sensient Technologies Corp. (SXT), reported transactions dated 09/30/2025 on Form 4. The filing shows a disposition of 21,414.266 shares of common stock and the acquisition by deferral of 389.185 deferred stock that converts one-for-one into common shares. After these entries the report lists 22,776.623 shares of common stock beneficially owned on a direct basis. The filing states the disposed shares include restricted stock and dividend reinvestment plan holdings, and the deferred shares result from deferral of director fees under the company’s directors’ deferred compensation plan. The signature was filed by an attorney-in-fact on behalf of Dr. Carleone.

Positive

• Director retains direct ownership of 22,776.623 common shares after transactions
• Deferred compensation converted to deferred stock under the Directors' Deferred Compensation Plan, aligning pay with equity

Negative

• Disposition of 21,414.266 common shares was reported, indicating a reduction in this director's holdings

Insights

Financial Analyst

TL;DR: Routine insider share disposition and fee deferral leave the director with a modest direct stake of 22,776.623 shares; no new derivative exposure.

The Form 4 documents a sale or other disposition of 21,414.266 common shares and a contemporaneous deferral credit of 389.185 deferred shares that convert to common stock. The net reported direct holding is 22,776.623 shares. There are no option exercises, new derivatives, or pledge statements disclosed. For investors this appears to be an ordinary director compensation deferral combined with a reduction in certain share holdings rather than a board-level governance change or corporate action.

Corporate Governance Expert

TL;DR: Disclosure reflects standard director compensation mechanics and routine changes in beneficial ownership; reporting is complete and timely.

The filing specifies that deferred stock arises from the issuer’s Directors' Deferred Compensation Plan and converts one-for-one to common stock. The declaration that some shares are restricted or held via dividend reinvestment is consistent with typical insider holdings. The report was signed by an attorney-in-fact and includes the required explanations about issuance upon termination of service. This is a routine Section 16 disclosure with no governance red flags identified in the document itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Carleone Joseph

(Last) (First) (Middle)

777 EAST WISCONSIN AVENUE

(Street)

MILWAUKEE WI 53202

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SENSIENT TECHNOLOGIES CORP [ SXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								21,414.266(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock	(2)	09/30/2025		A(3)		389.185		(4)	(4)	Common Stock	389.185	$0	22,776.623	D

Explanation of Responses:

1. Includes shares of restricted stock held under Issuer's 2017 Stock Plan, as amended and restated, and shares held in a dividend reinvestment plan.

2. Deferred stock converts to common stock on a one-for-one basis.

3. Deferral of director fees under Issuer's Directors' Deferred Compensation Plan.

4. Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer.

	/s/ John J. Manning, Attorney-in-Fact for Dr. Carleone	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did SXT director Dr. Joseph Carleone report on Form 4?

The filing reports a disposition of 21,414.266 common shares and acquisition by deferral of 389.185 deferred stock dated 09/30/2025.

How many shares does Dr. Carleone beneficially own after the reported transactions?

The Form 4 shows 22,776.623 shares of common stock beneficially owned on a direct basis following the reported transactions.

What is the nature of the deferred stock reported in the SXT Form 4?

The deferred stock results from deferral of director fees under the company’s Directors' Deferred Compensation Plan and converts to common stock on a one-for-one basis.

Did the Form 4 report any options, warrants, or other derivatives for SXT?

No. The filing contains no new option, warrant, put, call, or other derivative security entries; only deferred stock and common stock transactions are reported.

When were the transactions in the SXT Form 4 executed?

The reported transaction date is 09/30/2025 and the Form 4 was signed on 10/01/2025 by an attorney-in-fact.

Are the disposed shares described as restricted or held in a plan?

Yes. The filing states the disposed shares include restricted stock under the 2017 Stock Plan and shares held in a dividend reinvestment plan.